Treating osteoporosis by targeting parathyroid hormone to bone

Drug Discovery Today

Volumn 19, Issue 3, 2014, Pages 204-208

  Ponnapakkam, T ^a   Katikaneni, R ^a   Sakon, J ^b   Stratford, R ^c   Gensure, R C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS   (United States)

^c XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN BINDING PROTEIN; PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE; ANABOLIC AGENT; DELAYED RELEASE FORMULATION; PARATHYROID HORMONE;

BONE; BONE DENSITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG TARGETING; HUMAN; HYPERCALCEMIA; NONHUMAN; OSTEOPOROSIS; PUBLIC HEALTH PROBLEM; REVIEW; SINGLE DRUG DOSE; TREATMENT PLANNING; ANIMAL; CHEMICALLY INDUCED; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; METABOLISM; PATHOLOGY; RAT;

ANABOLIC AGENTS; ANIMALS; BONE AND BONES; DELAYED-ACTION PREPARATIONS; DIPHOSPHONATES; DRUG DELIVERY SYSTEMS; HYPERCALCEMIA; OSTEOPOROSIS; PARATHYROID HORMONE; RATS;

EID: 84896405316     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.07.015     Document Type: Short Survey

References (30)

1. OFN. National Osteoporosis Foundation
2. R. Burge et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J. Bone Miner. Res. 22 2007 465 475 (Pubitemid 46797130)
3. B. Dawson-Hughes et al. The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008 Osteoporos. Int. 23 2012 811 820
4. J. Iwamoto et al. Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature Clin. Intervent. Aging 3 2008 483 489
5. M.C. Hochberg et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group Arthritis Rheum. 42 1999 1246 1254 (Pubitemid 29268962)
6. J.M. Hollander, and J.I. Mechanick Bisphosphonates and metabolic bone disease in the ICU Curr. Opin. Clin. Nutr. Metab. Care 12 2009 190 195
7. K. Traynor FDA advisers uneasy about long-term bisphosphonate use Am. J. Health. Syst. Pharm. 68 2011 2006, 2008
8. J.E. Rossouw et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333 (Pubitemid 34761611)
9. T. Lin et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis Int. J. Clin. Pract. 66 2012 399 408
10. K. Brixen et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial J. Clin. Endocrinol. Metab. 98 2013 571 580
11. R.S. Rittmaster et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate J. Clin. Endocrinol. Metab. 85 2000 2129 2134 (Pubitemid 32269232)
12. E.M. Lewiecki et al. Osteoporosis update from the 2012 Santa Fe Bone symposium J. Clin. Densitom. 2013 S1094 S6950
13. K.E. Poole, and J. Reeve Parathyroid hormone - a bone anabolic and catabolic agent Curr. Opin. Pharmacol. 5 2005 612 617 (Pubitemid 41614461)
14. R.M. Neer et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N. Engl. J. Med. 344 2001 1434 1441 (Pubitemid 32402100)
15. J.L. Vahle et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose Toxicol. Pathol. 32 2004 426 438 (Pubitemid 38998935)
16. P.D. Miller Safety of parathyroid hormone for the treatment of osteoporosis Curr. Osteopor. Rep. 6 2008 12 16
17. M.E. Brunkow et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein Am. J. Hum. Genet. 68 2001 577 589 (Pubitemid 32202753)
18. R.M. McClung et al. Inhibition of sclerostin with AMG 785 in postmenopausal women with low bone mineral density: phase 2 trial results J. Bone Miner. Res. 27 Suppl 1 2012
19. Emisphere Oral Recombinant Parathyroid Hormone 2011
20. T. Matsumoto et al. Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study Osteoporos. Int. 17 2006 1532 1538 (Pubitemid 44387488)
21. F. Cosman et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women J. Clin. Endocrinol. Metab. 95 2010 151 158
22. P.J. Kostenuik et al. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone J. Bone Miner. Res. 22 2007 1534 1547 (Pubitemid 351229324)
23. L.M. Calvi et al. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone J. Clin. Invest. 107 2001 277 286 (Pubitemid 32157960)
24. O. Matsushita et al. A study of the collagen-binding domain of a 116-kDa Clostridium histolyticum collagenase J. Biol. Chem. 273 1998 3643 3648 (Pubitemid 28109790)
25. T. Toyoshima et al. Collagen-binding domain of a Clostridium histolyticum collagenase exhibits a broad substrate spectrum both in vitro and in vivo Connect. Tissue Res. 42 2001 281 290 (Pubitemid 33138550)
26. T. Ponnapakkam et al. Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice Calcif. Tissue Int. 88 2011 511 520
27. T. Ponnapakkam et al. A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice Calcif. Tissue Int. 91 2012 196 203
28. H. Dobnig, and R.T. Turner The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats Endocrinology 138 1997 4607 4612 (Pubitemid 27460894)
29. S.W. Kim et al. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts J. Bone Miner. Res. 27 2012 2075 2084
30. R. van Furth The origin of phagocytic cells in the joint and bone Scand. J. Rheumatol. Suppl. 40 1981 13 20 (Pubitemid 12113252)